Assignee: Knoll Aktiengesellschaft

Location: Ludwigshafen, DE
No. of patents: 56

Browse patents
Browse applications

Number	Title	Issue Date
6617360	Medical treatment A compound of formula I ##STR1## or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optiona...	09/09/2003
6509493	Method for producing atropic acid ethyl ester A process for preparing ethyl atropate by reacting ethyl phenylacetate with paraformaldehyde in the presence of a base is described and entails employing as ethyl phenylacetate a product which contains not more than 0.03% of the corresponding methyl pheny...	01/21/2003
6500830	Conversion of modification D to modification A of doxazosin mesylate A process for preparing doxazosin mesylate in modification A which comprises dissolving doxazosin with methanesulfonic acid in methanol or a mixture of an aprotic, polar organic solvent and methanol, removing any turbidity from the resulting solution, and...	12/31/2002
6458842	Liquid pharmaceutical compositions comprising thyroid hormones There is disclosed a liquid pharmaceutical composition comprising a therapeutic agent which comprises: one or more thyroid hormone or hormones; from about 40% to about 96% ethanol by volume; a pH adjusting agent so that the measured pH of the composition ...	10/01/2002
6353002	Therapeutic agents Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which A is methylene or --O--; B is methylene or --O--; G1 --G2 --G3 form a heteroaromatic or heteroaliphatic chain; g is 0, 1 or 2; U is an ...	03/05/2002
6312687	Stabilized lactoperoxidase and glucose oxidase concentrate A stabilized aqueous enzyme concentrate composition which comprises: a) 1000 to 1800 units/ml of lactoperoxidase; b) 1500 to 2750 units/ml of glucose oxidase; c) 10 to 20% w/v of an alkali metal halide salt; and d) a chelating buffering agent present in an amount such t...	11/06/2001
6271348	Tetracycline-inducible transcriptional inhibitor fusion proteins Methods of regulating gene expression in subjects using tetracycline-responsive fusion proteins are disclosed. In one embodiment, the method involves introducing into a cell the subject a nucleic acid molecule encoding a fusion protein which inhibits tran...	08/07/2001
6251945	Pharmaceutical mixture comprising a combination of a profen and other active compounds A pharmaceutical mixture comprising a profen and one or more additional active compounds is described which has a total active compound content of over 85% and contains up to 1%, based on the content of the profen, of a nonionic surfactant having an HLB o...	06/26/2001
6239165	Liquid pharmaceutical formulation containing zotepine A liquid pharmaceutical formulation comprising a) 2 to 7% w/v of Zotepine; b) 0.5 to 35% w/v of an organic acid selected from the group consisting of ascorbic acid, citric acid, fumaric acid, glutaric acid, lactic acid, malic acid, sorbic acid and tartari...	05/29/2001
6235281	Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6 The invention relates to the use of TNF antagonists for producing drugs for the treatment of disorders characterized by elevated serum levels of interleukin-6....	05/22/2001
6225469	Process for the preparation of 7-alkoxyalkyl-1,2,4-triazolo[1,5-A] pyrimidine derivatives An improved process for the preparation of 1,2,4-triazolo[1,5-a]pyrimidine compounds comprising the reaction involving a compound of formula II ##STR1## and a compound of formula III ##STR2## in the presence of an oxidizing agent and a reducing agent, whe...	05/01/2001
6215001	Imidazole derivatives as therapeutic agents Compounds of the formula I ##STR1## and pharmaceutically acceptable salts thereof in which R1 represents hydrogen, halo, cyano, cyanoalkyl, alkyl, alkoxy, phenoxy, phenyl, alkoxycarbonyl, --NR13 R14, --N(R15)SO	04/10/2001
6201004	Dioxino derivatives and their use as therapeutic agents Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which A is methylene or --O--; B is methylene or --O--; G1 --G2 --G3 form a heteroaromatic or heteroaliphatic chain; g is 0, 1 or 2; U is an ...	03/13/2001
6200791	Method of purifying thrombin-like protease enzymes obtained from snake venom A process for purifying thrombin-like proteases from snake venoms is described, which consists in freeing the proteases from impurities in three chromatographic steps: a) affinity or anion exchange, b) adsorption onto a glass matrix at alkaline pH values,...	03/13/2001
6197780	Method for combating obesity Diseases caused by obesity are treated with endothelin receptor antagonists. Diseases treated include those frequently associated with obesity such as hypertension, type 2 diabetes, hyperlipidemia, chronic kidney failure, arteriosclerosis and gout....	03/06/2001
6197349	Particles with modified physicochemical properties, their preparation and uses Particles comprising (a) a supercooled melt of a poorly water-soluble substance and (b) a stabilizing agent, which have a mean particle size of between 30 and 500 nm, and disperse compositions containing them, as administration forms and delivery systems for d...	03/06/2001
6187820	Medical treatment to improve lipid levels A compound of formula I ##STR1## or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optiona...	02/13/2001
6187802	Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use Compounds of Formula I ##STR1## including pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers, in which Ar is phenyl, naphthyl or benzo[b]thiophenyl, each of which may be option...	02/13/2001
6174925	Use of sibutramine analogues to prevent the development of diabetes A compound of formula (I) or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the f...	01/16/2001
6162831	Medical treatment to lower uric acid levels A compound of formula I ##STR1## or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride op...	12/19/2000
6146626	Defined enzyme mixtures for obtaining cells and treating wounds The invention relates to the use of mixtures of defined composition of purified enzymes from Clostridium histolyticum for obtaining, in a reproducible, standardized manner, cells or tissue fragments from human or animal tissues, and to these enzymes and m...	11/14/2000
6133267	Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications A compound of formula I ##STR1## or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example 1,1-dimethyl-2-(2-morpholinophenyl)guanidine fumarate) is used for inhibiting the ...	10/17/2000
6127424	Aryl-substituted cyclobutylalkylamines for treating obesity Use of aryl-substituted cyclobutylalkylamines and their pharmaceutically suitable salts for treating obesity and its accompanying disorders are disclosed....	10/03/2000
6114334	Piperazine derivatives as therapeutic agents Substituted piperazine compounds of formula I ##STR1## in which HET is a substituted pyrazole, imidazole or 1,2,4-triazole have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schi...	09/05/2000
6107310	Heteroarylcarboxamide derivatives for treating CNS disorders Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which A is methylene or --O--; B is methylene or --O--; G1 --G2 --G3 are absent or form a heteroaromatic chain; g is 0,1,2,3 or 4; U is ...	08/22/2000
6031109	Phenoxy-, phenylthio-, benzoyl-alkyleneaminoalkylene-imidazole derivatives as therapeutic agents Compounds of formula I ##STR1## where R1 -R3, L1, T, L2 --N--Q--Y and R6 are as defined in the specification, and pharmaceutically acceptable salts thereof which are antiinflammatory, antiallergi...	02/29/2000
5935973	Heterocyclcarboxamide derivatives and their use as therapeutic agents Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which A is methylene or O; B is methylene or O; g is 0,1,2,3 or 4; R1 is an optional substituent; U is an alkylene chain optionally substituted by one or more...	08/10/1999
5917087	Process for producing sodium 1-thyroxine comprising the oxidative coupling of a diido-1-tyrosine catalysed by a manganese salt in the presence of an amine Improvements to a six stage process for production of sodium l-thyroxine from l-tyrosine described in U.S. Pat. No. 2,889,363 and U.S. Pat. No. 2,889,364 (Baxter)! are described, the improvements comprising the oxidative coupling of a diiodo-l-thyrosine...	06/29/1999
5905079	1,2,4-triazolo4,3-b!pyridazine derivatives and their use Certain 1,2,4-triazolo(4,3-b)pyridazines of formula ##STR1## including pharmaceutically acceptable salts thereof, wherein R1 -R8 are as defined in the disclosure, for the treatment, prophylaxis and/or inhibition of seizures, neu...	05/18/1999
5888981	Methods for regulating gene expression A method for regulating expression of a tet operator-linked gene in a cell of a subject is disclosed. In one embodiment, the method involves introducing into the cell a nucleic acid molecule encoding a tetracycline-controllable transactivator (tTA), the t...	03/30/1999
5869492	Condensed thiazole derivatives, having 5-HT receptor affinity Compounds of formula I ##STR1## in which A is S(O)p or O; p is 0, 1 or 2; g is 0, 1, 2, 3, or 4; n is 2 or 3; and R1, R2, R3, R4 and R5 are optional substituents have utility in the treatme...	02/09/1999
5854257	Naphthyridinone derivatives Compounds of formula I ##STR1## including pharmaceutically acceptable salts thereof in which R1 represents a phenyl C1-6 alkyl group (in which the phenyl ring is optionally substituted by one or more of the following: halo, a C	12/29/1998
5847216	Preparation of selegiline A process for preparing selegiline hydrochloride by reaction of R-(-)-N,଱-dimethylphenylethylamine with 3-bromo-1-propyne is described, which consists in reacting the substances in a molar ratio of approximately 2:1 at 30°-50° C. in a solvent mixt...	12/08/1998
5814618	Methods for regulating gene expression Methods of regulating gene expression in subjects using tetracycline-responsive fusion proteins are disclosed. In one embodiment, the method involves introducing into a cell the subject a nucleic acid molecule encoding a fusion protein which inhibits tran...	09/29/1998
5807542	Chemical compositions for inhibiting nitrosation reaction in toiletries and cosmetics Iminium ion scavengers are used in the invention to inhibit formation of N-nitrosamines, especially in cosmetics and pharmaceuticals formulations. The iminium ion scavengers may be used in combination with nitrite ion scavengers such as ascorbate....	09/15/1998
5807868	Isoquinoline derivatives as therapeutic agents Tetrahydroisoquinoline compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof, in which: R1 represents one or more substituents selected from H, halo, hydroxy, alkyl (optionally substituted by hydroxy), alkoxy, alkyl...	09/15/1998
5804586	Therapeutic agents Tetrahydroisoquinoline compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof, in which: R1 represents one or more substituents selected from H, halo, hydroxy, alkyl (optionally substituted by hydroxy), alkoxy, alkyl...	09/08/1998
5780482	Condensed 4-aminopyridines with antirheumatic activity Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or C--R3 ; R1 represents hydrogen, halo, alkyl, hydroxy, carboxyalkenyl, alkoxycarbonyl...	07/14/1998
5776911	Use of (S)-adenosyl-l-methionine (same) and its physiologically tolerated salts for treating reperfusion damage caused by temporary focal ischemia SAMe and its physiologically tolerated salts are administered to a patient for the treatment of reperfusion damage caused by temporary focal ischemia....	07/07/1998
5767116	Bicyclic aromatic compounds as therapeutic agents Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which A is methylene or --O--; B is methylene or --O--; and g is 0, 1, 2, 3 or 4; R1, R2, R3, R4, U, Q and T are defined in claim ...	06/16/1998

«First «Previous1 2 Next»Last»

PatentStorm

Bizarre Patents

PatentStorm News

Assignee: Knoll Aktiengesellschaft